gardasil vaccine china

China, Merck and Gardasil

Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

The Associated Press - Busines… · 8h

Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

AOL · 6h

Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange,

STAT46m

Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

FiercePharma7h

Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

MSD shares sink 11% after vaccine shipments to China halted

Drugmaker pauses HPV Gardasil exports as rival Pfizer gets boost from better than expected Covid vaccine and pill sales ...

BioSpace8h

Merck’s Gardasil Woes Grow as China Trade War Heats Up

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

China, Merck and Gardasil

Related topics